Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Biogen Inc.

A Decade of SG&A: Gilead Sciences vs. Biogen

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, Gilead Sciences, Inc. and Biogen Inc. have demonstrated contrasting approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead's SG&A expenses surged by over 100%, peaking at $6.09 billion in 2023. This reflects a strategic investment in marketing and administrative capabilities, likely to support its expanding product portfolio. In contrast, Biogen's SG&A expenses grew more modestly, with a 14% increase over the same period, reaching $2.55 billion in 2023. This conservative growth suggests a focus on cost efficiency and targeted spending. These financial strategies highlight the distinct paths these companies are taking in a competitive market, offering insights into their operational priorities and future directions.